Cardiac Optical Coherence Tomography: History, Current Status, and Perspective.
acute coronary syndrome
optical coherence tomography
percutaneous coronary intervention
plaque
Journal
JACC. Asia
ISSN: 2772-3747
Titre abrégé: JACC Asia
Pays: United States
ID NLM: 9918452380106676
Informations de publication
Date de publication:
Feb 2024
Feb 2024
Historique:
received:
30
06
2023
revised:
05
09
2023
accepted:
02
10
2023
medline:
19
2
2024
pubmed:
19
2
2024
entrez:
19
2
2024
Statut:
epublish
Résumé
For more than 2 decades since the first imaging procedure was performed in a living patient, intravascular optical coherence tomography (OCT), with its unprecedented image resolution, has made significant contributions to cardiovascular medicine in the realms of vascular biology research and percutaneous coronary intervention. OCT has contributed to a better understanding of vascular biology by providing insights into the pathobiology of atherosclerosis, including plaque phenotypes and the underlying mechanisms of acute coronary syndromes such as plaque erosion, neoatherosclerosis, stent thrombosis, and myocardial infarction with nonobstructive coronary arteries. Moreover, OCT has been used as an adjunctive imaging tool to angiography for the guidance of percutaneous coronary intervention procedures to optimize outcomes. However, broader application of OCT has faced challenges, including subjective interpretation of the images and insufficient clinical outcome data. Future developments including artificial intelligence-assisted interpretation, multimodality catheters, and micro-OCT, as well as large prospective outcome studies could broaden the impact of OCT on cardiovascular medicine.
Identifiants
pubmed: 38371282
doi: 10.1016/j.jacasi.2023.10.001
pii: S2772-3747(23)00289-2
pmc: PMC10866736
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
89-107Informations de copyright
© 2024 The Authors.
Déclaration de conflit d'intérêts
Dr Jang received an educational grant from Abbott Medical; and served on the clinical end point committee for Svelte Medical System. Dr Yonetsu has reported that he has no relationships relevant to the contents of this paper to disclose.